TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21908036
Drug: Dalcetrapib 600
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 600 mg/day for 24 months
Study: 19264836
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine administered at 0, 6 and 14 weeks
Study: 19264836
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine administered at 6, 10 and 14 weeks
Study: 16174858
Drug: Estrogen-plus-progestin therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-plus-progestin therapy (0.625 mg conjugated equine estrogens + 2.5 mg medroxyprogesterone acetate)
Study: 11823394
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg with lidocaine 0.5% (3 mg.kg(‐1))
Study: 7721498
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 20 mg three times daily
Study: 2248921
Drug: DexSol containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DexSol containing recombinant hEGF and human insulin
Study: 6113234
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Prazeapm, Diazepam, Lorazepam, Placebo)
Study: 30622223
Drug: Group LB:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group LB: 20 ml 0.25% levobupivacaine + 0.3 mg (1 ml) buprenorphine
Study: 30622223
Drug: Group LD:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group LD: 20 ml 0.25% levobupivacaine + 4 mg (1 ml) dexamethasone
Study: 30622223
Drug: Group L:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L: 20 ml 0.25% levobupivacaine + 1 ml normal saline (NS)
Study: 28640161
Drug: Intravaginal 0.50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal 0.50% (6.5 mg) prasterone
Study: 19679575
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (regular training activity without treatment)
Study: 12353677
Drug: 0.5% fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% fluorouracil cream for 1 week
Study: 12353677
Drug: 0.5% fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% fluorouracil cream for 2 weeks
Study: 12353677
Drug: 0.5% fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% fluorouracil cream for 4 weeks
Study: 10407503
Drug: Antioxidant vitamins
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamins (150 mg ascorbic acid, 67 mg alpha-tocopherol, 9 mg beta-carotene)
Study: 10407503
Drug: B group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: B group vitamins (1 mg folic acid, 7.2 mg pyridoxine, 0.02 mg cyanocobalamin)
Study: 6113858
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg terfenadine suspension
Study: 6113858
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg terfenadine suspension
Study: 6113858
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of 14C terfenadine
Study: 6113858
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of 14C
Study: 28849773
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose (20 µg) hepatitis B vaccine
Study: 28849773
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (10 µg) hepatitis B vaccine
Study: 25670366
Drug: Anacetrapib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib (150 and 300 mg/d)
Study: 25670366
Drug: Anacetrapib +
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib + Atorvastatin
Study: 25670366
Drug: Atorvastatin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin alone vs placebo
Study: 22711385
Drug: Multivitamin, mineral
Normalized name: multivitamin, minerals no.51/folic acid/vit K1/ubidecarenone 100 mcg-350 mcg-5 mg ORAL TABLET,CHEWABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin, mineral and herbal supplement (Swisse Men's Ultivite®)
Study: 17376293
Drug: nateglinide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: nateglinide (120 mg)
Study: 15736118
Drug: acarbose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: acarbose (50 mg)
Study: 15199325
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of non-nucleoside reverse transcriptase inhibitors (NNRTI) from current therapy
Study: 15199325
Drug: Non-nucleoside reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nucleoside reverse transcriptase inhibitors (NNRTI)
Study: 1190686
Drug: Methylprednisolone, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone, 10 mg/kg intravenously at 8-hour intervals for three doses
Study: 22334056
Drug: Aerobic training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic training (50 minutes, four times weekly for 24 weeks)
Study: 22334056
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (health lectures twice a month)
Study: 23565931
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment for hypertension
Study: 18549492
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care interventions (three step treatment approach: step 1 - behavioural change counselling, step 2 - three sessions of motivational enhancement therapy, step 3 - referral to specialist services)
Study: 12610040
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine prebedtime plus lispro preprandially (LIS/GLAR)
Study: 12610040
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin prebedtime plus regular human insulin preprandially (R/NPH)
Study: 31212997
Drug: Neo-adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant chemotherapy
Study: 7577201
Drug: Less extensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less extensive treatment
Study: 31932201
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplement 2000 IU per day for 2 months
Study: 26988095
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention for GPs on inhalation techniques (one session with a monitor)
Study: 20205074
Drug: Asenapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine (5 or 10 mg BID)
Study: 22454251
Drug: Olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10 or 20 mg QD)
Study: 18021264
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin 1 g, 1 h pre-operatively and 2 g for 2 days post-operatively (Antibiotics group)
Study: 18021264
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (Non-antibiotics group)
Study: 9197875
Drug: Continuous 17
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 17 beta‐oestradiol orally (2 mg daily)
Study: 9197875
Drug: Continuous 17
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 17 beta‐oestradiol transdermally (50 micrograms daily)
Study: 1527230
Drug: Methylphenidate or
Normalized name: methylphenidate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate or dextroamphetamine in individualized doses
Study: 23611825
Drug: Cholecalciferol supplementation
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol supplementation (100,000 IU orally every 3 months for 4 doses)
Study: 19926166
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antibiotics unless clinically indicated)
Study: 1582188
Drug: Oxprenolol (non-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (non-selective beta-blocker with moderate intrinsic sympathomimetic activity), given by the Oros delivery system
Study: 1582188
Drug: Atenolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta 1-selective blocker without ISA)
Study: 23536963
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of black pepper essential oil for 2 minutes
Study: 23536963
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of angelica essential oil for 2 minutes
Study: 15161771
Drug: Pioglitazone (P+)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (P+) 45 mg for 21 days
Study: 12101864
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg or 600 mg) and Misoprostol (400 micrograms)
Study: 12101864
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg or 600 mg) and Misoprostol (600 micrograms)
Study: 12101864
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg and Misoprostol (400 micrograms)
Study: 9867054
Drug: Clinical benefits
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical benefits of steroids
Study: 2536867
Drug: Regimen B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B: two courses of three sequential drug combinations (1) cyclophosphamide, lomustine, and methotrexate; (2) cyclophosphamide, doxorubicin, and vincristine; (3) ifosfamid and etoposide
Study: 9388412
Drug: Brassiodol (iodised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brassiodol (iodised rapeseed oil) at a dose of 2 mL
Study: 3279725
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg b.i.d. with moderate dietary salt reduction
Study: 3279725
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg b.i.d. with hydrochlorothiazide 25 mg daily
Study: 17581217
Drug: Benazepril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (10 mg/day, p.o.)
Study: 15699266
Drug: avasimibe 750
Normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
Approvals — FDA: no, EMA: no, PMDA: no
Description: avasimibe 750 mg QDS for 8 weeks
Study: 10544534
Drug: nasally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasally administered continuous positive airway pressure (CPAP) therapy
Study: 10544534
Drug: recent technological
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: recent technological developments in CPAP therapy
Study: 10544534
Drug: semiattended and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: semiattended and unattended settings for CPAP therapy
Study: 23123345
Drug: Doxycycline (200mg/day)
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline (200mg/day) for 23 days followed by doxycycline (200mg/day) in combination with albendazole (ABZ) (400mg/day) for 7 days
Study: 23123345
Drug: Doxycycline and
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline and ABZ in combination
Study: 19514296
Drug: Combined therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapeutic modalities with magnetopuncture therapy
Study: 19514296
Drug: Combined therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapeutic modalities without magnetopuncture therapy
Study: 16691061
Drug: 6% cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% cellulose sulfate (CS) gel
Study: 11350571
Drug: High-dose nimodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nimodipine (2-mg h(-1))
Study: 11350571
Drug: Low-dose nimodipine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nimodipine (1-mg h(-1))
Study: 8498421
Drug: 587 mg
Normalized name: choline salicylate 587 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 587 mg calcium per day
Study: 8498421
Drug: 1336 mg
Normalized name: Mg
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1336 mg calcium per day
Study: 8498421
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg manganese per day
Study: 8498421
Drug: 5.6 mg
Normalized name: menthol 5.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.6 mg manganese per day
Study: 2958819
Drug: Methylprednisolone 40
Normalized name: methylprednisolone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 40 mg intramuscularly and intravenously
Study: 31885292
Drug: Positive mycoplasma
Normalized name: Mycoplasma pneumoniae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive mycoplasma pneumoniae (MP) antibody IgM
Study: 31913413
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel alone or with carboplatin and/or veliparib for 12 weeks followed by 4 cycles of doxorubicin hydrochloride and cyclophosphamide
Study: 31913413
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel alone or with carboplatin and/or veliparib
Study: 25372086
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (25 mg etanercept plus methotrexate)
Study: 16549707
Drug: 3-injection site
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-injection site pattern (3 injections of 10 U of botulinum toxin A)
Study: 16549707
Drug: 5-injection site
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-injection site pattern (5 injections of 10 U of botulinum toxin A)
Study: 25517733
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 injections)
Study: 16549707
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 injections)
Study: 11156724
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enoxaparin and abciximab
Study: 9052285
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg of dexamethasone
Study: 30990088
Drug: Dyadic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyadic treatment (STAND)
Study: 30944269
Drug: Metformin 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1,500 mg/d
Study: 19796088
Drug: Li-PDT-PC (5-ALA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Li-PDT-PC (5-ALA 0.5% liposomal spray and intense pulsed light in combination with topical peeling agents)
Study: 19796088
Drug: Li-PDT-PC-AT (Li-PDT-PC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Li-PDT-PC-AT (Li-PDT-PC with additional topical or systemic antibiotics)
Study: 18428095
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment plus three-weekly CM sessions for 5 weeks
Study: 16804925
Drug: Prior chemotherapy
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior chemotherapy
Study: 12563672
Drug: Anakinra (0.04,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (0.04, 0.1, 0.4, 1, or 2 mg/kg once daily for 24 weeks)
Study: 12563672
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in addition to MTX 15 to 25 mg/wk)
Study: 1862257
Drug: Erdosteine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine (300 mg t.i.d.) for 8 days
Study: 31693746
Drug: Mean arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean arterial pressure treatment only (Group 1)
Study: 24059983
Drug: Intensive integrative
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive integrative language therapy (at least 2 hours/day and at least 10 hours/week for at least three weeks)
Study: 19522426
Drug: Clomifene citrate
Normalized name: Clomifene citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomifene citrate plus metformin 850 mg two times a day
Study: 17308899
Drug: Olpadronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpadronate (10 mg/m2/day)
Study: 14973308
Drug: PNU-96391 1
Normalized name: Alternaria alternata allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNU-96391 1 mg
Study: 14973308
Drug: PNU-96391 3
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNU-96391 3 mg
Study: 14973308
Drug: PNU-96391 10
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNU-96391 10 mg
Study: 14973308
Drug: PNU-96391 30
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNU-96391 30 mg
Study: 14973308
Drug: PNU-96391 100
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNU-96391 100 mg
Study: 14973308
Drug: PNU-96391 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNU-96391 150 mg
Study: 14973308
Drug: PNU-96391 200
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNU-96391 200 mg
Study: 9054234
Drug: 21-mg/day nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21-mg/day nicotine patches
Study: 9054234
Drug: 14-mg/day nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-mg/day nicotine patches
Study: 9054234
Drug: 7-mg/day nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-mg/day nicotine patches
Study: 7946592
Drug: CAF +
Normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAF + MPA therapy (CAF: CPA 100 mg orally days 1-14, ADR 30 mg/m2 i.v. days 1 and 8, 5-FU 500 mg/m2 i.v. days 1 and 8; MPA 1200 mg daily)
Study: 7946592
Drug: CAF +
Normalized name: Caffeine and Sodium Benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAF + MPA therapy
Study: 7946592
Drug: CAF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF therapy (control)
Study: 29439648
Drug: Tiotropium/olodaterol 5/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium/olodaterol 5/5 µg
Study: 29439648
Drug: Tiotropium/olodaterol 2.5/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium/olodaterol 2.5/5 µg
Study: 21633921
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of circulating progenitor cells (CPC) or bone marrow-derived progenitor cells (BMC)
Study: 18350925
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy and radiotherapy
Study: 18350925
Drug: Palliative chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative chemotherapy, radiotherapy, and surgery
Study: 1516461
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg cefetamet syrup, given orally twice daily for 7 days
Study: 1516461
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg cefaclor, given orally twice daily for 7 days
Study: 30306325
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl tablet
Study: 26912469
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention by pharmacists to inform patients about adverse effects of medications
Study: 26912469
Drug: Patients unaware
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients unaware of adverse effects of medications
Study: 24368588
Drug: Chlorhexidine (CHX)
Normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (CHX) mouth rinsing twice daily and no brushing
Study: 20498245
Drug: MMF 3-g
Normalized name: glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 3-g arm (1.5 g twice daily on days 1 to 5, then 1.0 g twice daily)
Study: 20498245
Drug: MMF 2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 2-g arm (1.0 g twice daily)
Study: 20498245
Drug: MMF 3-g
Normalized name: glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 3-g arm
Study: 20498245
Drug: MPA AUC
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA AUC levels <30 mg.h/L
Study: 20498245
Drug: MMF 3-g
Normalized name: glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 3-g arm and MMF 2-g arm
Study: 17645881
Drug: 24 mg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg/min vitamin C
Study: 12043854
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension 0.25 mg twice daily
Study: 9819296
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension 0.50 mg twice daily
Study: 9819296
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension 1.0 mg twice daily
Study: 9819296
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (all doses)